
TD Cowen Initiates a Buy Rating on RAPT Therapeutics (RAPT)

I'm PortAI, I can summarize articles.
TD Cowen analyst Yaron Werber initiated a Buy rating on RAPT Therapeutics with a price target of $64.38. Werber, known for his strong track record in the Healthcare sector, has an average return of 24.4% and a 59.88% success rate on recommended stocks. RAPT Therapeutics holds a consensus Strong Buy rating among analysts.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

